Bristol-Myers Squibb Company (NYSE: BMY) Stock Competitors & Peer Comparison

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while LLY trades at $1,152.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas LLY's P/E ratio is 36.61. In terms of profitability, BMY's ROE is +0.47%, compared to LLY's ROE of +0.93%. Regarding short-term risk, BMY is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for BMY.Check LLY's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, JNJ has a market cap of 650.6B. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while JNJ trades at $269.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas JNJ's P/E ratio is 25.16. In terms of profitability, BMY's ROE is +0.47%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, BMY is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for BMY.Check JNJ's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, ABBV has a market cap of 466.1B. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while ABBV trades at $263.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas ABBV's P/E ratio is 25.89. In terms of profitability, BMY's ROE is +0.47%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, BMY is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for BMY.Check ABBV's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, MRK has a market cap of 362.5B. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while MRK trades at $146.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas MRK's P/E ratio is 45.72. In terms of profitability, BMY's ROE is +0.47%, compared to MRK's ROE of +0.07%. Regarding short-term risk, BMY is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for BMY.Check MRK's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, NVS has a market cap of 266.8B. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while NVS trades at $140.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas NVS's P/E ratio is 16.15. In terms of profitability, BMY's ROE is +0.47%, compared to NVS's ROE of +0.30%. Regarding short-term risk, BMY is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for BMY.Check NVS's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, AZN has a market cap of 257.5B. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while AZN trades at $166.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas AZN's P/E ratio is 17.93. In terms of profitability, BMY's ROE is +0.47%, compared to AZN's ROE of +0.22%. Regarding short-term risk, BMY is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for BMY.Check AZN's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, AMGN has a market cap of 205B. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while AMGN trades at $385.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas AMGN's P/E ratio is 16.98. In terms of profitability, BMY's ROE is +0.47%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, BMY is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for BMY.Check AMGN's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, NVO has a market cap of 192B. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while NVO trades at $43.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas NVO's P/E ratio is 10.76. In terms of profitability, BMY's ROE is +0.47%, compared to NVO's ROE of +0.59%. Regarding short-term risk, BMY is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for BMY.Check NVO's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, GILD has a market cap of 186.4B. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while GILD trades at $150.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas GILD's P/E ratio is -384.90. In terms of profitability, BMY's ROE is +0.47%, compared to GILD's ROE of -0.16%. Regarding short-term risk, BMY is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for BMY.Check GILD's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, PFE has a market cap of 157.3B. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while PFE trades at $27.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas PFE's P/E ratio is 9.05. In terms of profitability, BMY's ROE is +0.47%, compared to PFE's ROE of +0.05%. Regarding short-term risk, BMY is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for BMY.Check PFE's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, SNY has a market cap of 102B. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while SNY trades at $42.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas SNY's P/E ratio is 9.25. In terms of profitability, BMY's ROE is +0.47%, compared to SNY's ROE of +0.06%. Regarding short-term risk, BMY is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for BMY.Check SNY's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, GSK has a market cap of 100.6B. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while GSK trades at $50.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas GSK's P/E ratio is 10.85. In terms of profitability, BMY's ROE is +0.47%, compared to GSK's ROE of +0.24%. Regarding short-term risk, BMY is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for BMY.Check GSK's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, BIIB has a market cap of 31.8B. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while BIIB trades at $215.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas BIIB's P/E ratio is 13.60. In terms of profitability, BMY's ROE is +0.47%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, BMY is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for BMY.Check BIIB's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas HZNP's P/E ratio is 61.86. In terms of profitability, BMY's ROE is +0.47%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, BMY is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for BMY.Check HZNP's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, GRFS has a market cap of 6.2B. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while GRFS trades at $7.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas GRFS's P/E ratio is 8.40. In terms of profitability, BMY's ROE is +0.47%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, BMY is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for BMY.Check GRFS's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while OGN trades at $13.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas OGN's P/E ratio is 4.09. In terms of profitability, BMY's ROE is +0.47%, compared to OGN's ROE of +0.23%. Regarding short-term risk, BMY is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for BMY.Check OGN's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, AMRN has a market cap of 286.9M. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while AMRN trades at $13.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas AMRN's P/E ratio is -138.70. In terms of profitability, BMY's ROE is +0.47%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, BMY is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for BMY.Check AMRN's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, SCLX has a market cap of 42.8M. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while SCLX trades at $5.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas SCLX's P/E ratio is -0.13. In terms of profitability, BMY's ROE is +0.47%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, BMY is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for BMY.Check SCLX's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, MIRA has a market cap of 34.2M. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while MIRA trades at $0.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas MIRA's P/E ratio is -0.56. In terms of profitability, BMY's ROE is +0.47%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, BMY is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for BMY.Check MIRA's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, SCLXW has a market cap of 33.6M. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while SCLXW trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas SCLXW's P/E ratio is N/A. In terms of profitability, BMY's ROE is +0.47%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, BMY is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for BMY.Check SCLXW's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, BMY's ROE is +0.47%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, BMY is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for BMY.Check BDSIW's competition here

Bristol-Myers Squibb Company (NYSE: BMY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 128.8B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, BMY is priced at $63.06 on the NYSE, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 10.63, whereas CRXT's P/E ratio is -0.02. In terms of profitability, BMY's ROE is +0.47%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, BMY is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for BMY.Check CRXT's competition here